Capricor Therapeutics Stock Performance
| CAPR Stock | USD 19.06 0.24 1.28% |
Capricor Therapeutics holds a performance score of 19 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 0.16, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Capricor Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Capricor Therapeutics is expected to be smaller as well. Use Capricor Therapeutics semi variance, and the relationship between the treynor ratio and daily balance of power , to analyze future returns on Capricor Therapeutics.
Risk-Adjusted Performance
19 of 100
Weak | Strong |
Solid
Compared to the overall equity markets, risk-adjusted returns on investments in Capricor Therapeutics are ranked lower than 19 (%) of all global equities and portfolios over the last 90 days. Even with relatively unfluctuating basic indicators, Capricor Therapeutics reported solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 0.72 | Five Day Return 1.04 | Year To Date Return 270.21 | Ten Year Return (50.12) | All Time Return (95.79) |
Last Split Factor 1:10 | Dividend Date 2019-06-05 | Last Split Date 2019-06-05 |
1 | EXCLUSIVE Capricor Therapeutics Inks European Expansion, Commercialization Pact For Lead Asset With Japanese Pharma Firm | 09/17/2024 |
2 | Acquisition by Nippon Shinyaku Co Ltd of 2798507 shares of Capricor Therapeutics at 5.36 subject to Rule 16b-3 | 09/20/2024 |
3 | Is Capricor Therapeutics, Inc. the Best Russell 2000 Stock to Buy According to Analysts | 10/03/2024 |
4 | Acquisition by Kelliher Mike of 30000 shares of Capricor Therapeutics at 5.12 subject to Rule 16b-3 | 10/11/2024 |
5 | Capricor Therapeutics Announces Pricing of Approximately 75 Million Public Offering of Common Stock | 10/17/2024 |
6 | STAT Capricor and the FDA A daring, risky filing strategy | 10/31/2024 |
7 | OraSure Technologies Reports Q3 Loss, Tops Revenue Estimates | 11/06/2024 |
8 | Is Capricor Therapeutics Outperforming Other Medical Stocks This Year | 11/07/2024 |
9 | Heres Why Momentum in Capricor Should Keep going | 11/11/2024 |
10 | Capricor Therapeutics earnings missed by 0.02, revenue fell short of estimates | 11/13/2024 |
11 | Earnings call Capricor outlines deramiocels path to market for DMD treatment | 11/14/2024 |
12 | Capricor stock on watch after key EU designations | 11/20/2024 |
13 | Capricor Therapeutics Stock Surges Amid Positive Analyst Ratings | 11/22/2024 |
| Begin Period Cash Flow | 9.6 M |
Capricor |
Capricor Therapeutics Relative Risk vs. Return Landscape
If you would invest 469.00 in Capricor Therapeutics on August 28, 2024 and sell it today you would earn a total of 1,437 from holding Capricor Therapeutics or generate 306.4% return on investment over 90 days. Capricor Therapeutics is currently generating 2.7408% in daily expected returns and assumes 11.3541% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Capricor, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Capricor Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Capricor Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Capricor Therapeutics, and traders can use it to determine the average amount a Capricor Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2414
| Best Portfolio | Best Equity | |||
| Good Returns | CAPR | |||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 11.35 actual daily | 96 96% of assets are less volatile |
Expected Return
| 2.74 actual daily | 54 54% of assets have lower returns |
Risk-Adjusted Return
| 0.24 actual daily | 19 81% of assets perform better |
Based on monthly moving average Capricor Therapeutics is performing at about 19% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Capricor Therapeutics by adding it to a well-diversified portfolio.
Capricor Therapeutics Fundamentals Growth
Capricor Stock prices reflect investors' perceptions of the future prospects and financial health of Capricor Therapeutics, and Capricor Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Capricor Stock performance.
| Return On Equity | -3.93 | ||||
| Return On Asset | -0.44 | ||||
| Profit Margin | (1.47) % | ||||
| Operating Margin | (5.75) % | ||||
| Current Valuation | 772.36 M | ||||
| Shares Outstanding | 45.47 M | ||||
| Price To Earning | 42.39 X | ||||
| Price To Book | 12.54 X | ||||
| Price To Sales | 36.84 X | ||||
| Revenue | 25.18 M | ||||
| Gross Profit | 1.75 M | ||||
| EBITDA | (23.01 M) | ||||
| Net Income | (22.29 M) | ||||
| Cash And Equivalents | 51.42 M | ||||
| Cash Per Share | 2.11 X | ||||
| Total Debt | 2.24 M | ||||
| Debt To Equity | 0.15 % | ||||
| Current Ratio | 2.69 X | ||||
| Book Value Per Share | 0.73 X | ||||
| Cash Flow From Operations | (25.6 M) | ||||
| Earnings Per Share | (1.03) X | ||||
| Market Capitalization | 855.74 M | ||||
| Total Asset | 58.73 M | ||||
| Retained Earnings | (159.37 M) | ||||
| Working Capital | 19.59 M | ||||
| Current Asset | 22.4 M | ||||
| Current Liabilities | 6.67 M | ||||
About Capricor Therapeutics Performance
Assessing Capricor Therapeutics' fundamental ratios provides investors with valuable insights into Capricor Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Capricor Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.38) | (0.40) | |
| Return On Capital Employed | (0.88) | (0.83) | |
| Return On Assets | (0.38) | (0.40) | |
| Return On Equity | (0.99) | (0.94) |
Things to note about Capricor Therapeutics performance evaluation
Checking the ongoing alerts about Capricor Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Capricor Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Capricor Therapeutics is way too risky over 90 days horizon | |
| Capricor Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 25.18 M. Net Loss for the year was (22.29 M) with profit before overhead, payroll, taxes, and interest of 1.75 M. | |
| Capricor Therapeutics currently holds about 51.42 M in cash with (25.6 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.11. | |
| Capricor Therapeutics has a very weak financial position based on the latest SEC disclosures | |
| Roughly 17.0% of the company shares are held by company insiders | |
| Latest headline from gurufocus.com: Capricor Therapeutics Stock Surges Amid Positive Analyst Ratings |
- Analyzing Capricor Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Capricor Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Capricor Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Capricor Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Capricor Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Capricor Therapeutics' stock. These opinions can provide insight into Capricor Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Capricor Stock Analysis
When running Capricor Therapeutics' price analysis, check to measure Capricor Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Capricor Therapeutics is operating at the current time. Most of Capricor Therapeutics' value examination focuses on studying past and present price action to predict the probability of Capricor Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Capricor Therapeutics' price. Additionally, you may evaluate how the addition of Capricor Therapeutics to your portfolios can decrease your overall portfolio volatility.